Literature DB >> 7786593

Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis?

P Terrier1, M Henry-Amar, T J Triche, M E Horowitz, M J Terrier-Lacombe, J S Miser, T J Kinsella, G Contesso, A Llombart-Bosch.   

Abstract

Among Ewing's sarcoma (ES) of bone and related entities are tumours with neuro-ectodermal features that could represent a biologically distinct type. In order to assess the prognostic significance of the various forms of ES, a retrospective joint study involving three cancer centres in Europe and the U.S.A. was initiated. The material from 315 primary ES was reviewed by a panel of five pathologists and classified as typical ES (220 cases), atypical ES (48 cases) or ES with neuro-ectodermal features (47 cases). Prognostic factor analysis on treatment failure-free survival was performed using the Cox model. It included histopathological classification, initial patient characteristics, clinical presentation and treatment type. After multivariate analysis, in addition to treatment type (P < 0.001), metastases (P = 0.003) and proximal tumour location (P = 0.006), two histopathological parameters correlated with poor treatment failure-free survival, the presence of filigree pattern (P = 0.044) and dark cells (P = 0.043). We conclude that ES with neuro-ectodermal features does not appear to have a different outcome to the other subtypes.

Entities:  

Mesh:

Year:  1995        PMID: 7786593     DOI: 10.1016/0959-8049(94)00417-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Lumbar region intra-spinal primitive neuroectodermal tumour (PNET) combined with neurofibromatosis type 1.

Authors:  Uriel Bohn Sarmiento; David Aguiar Bujanda; Rafael Camacho Galán; José C Rivero Vera; José Aguiar Morales
Journal:  Clin Transl Oncol       Date:  2005-11       Impact factor: 3.405

2.  Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.

Authors:  Antonio Llombart-Bosch; Isidro Machado; Samuel Navarro; Franco Bertoni; Patrizia Bacchini; Marco Alberghini; Apollon Karzeladze; Nikita Savelov; Semyon Petrov; Isabel Alvarado-Cabrero; Doina Mihaila; Philippe Terrier; Jose Antonio Lopez-Guerrero; Piero Picci
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

3.  Additional chromosome 1q aberrations and der(16)t(1;16), correlation to the phenotypic expression and clinical behavior of the Ewing family of tumors.

Authors:  B Stark; C Mor; M Jeison; R Gobuzov; I J Cohen; Y Goshen; J Stein; S Fisher; S Ash; I Yaniv; R Zaizov
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 4.  Ewing tumour: incidence, prognosis and treatment options.

Authors:  M Paulussen; B Fröhlich; H Jürgens
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Soft tissue tumors associated with EWSR1 translocation.

Authors:  Salvatore Romeo; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

6.  Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study).

Authors:  O Oberlin; M C Deley; B N Bui; J C Gentet; T Philip; P Terrier; C Carrie; F Mechinaud; C Schmitt; A Babin-Boillettot; J Michon
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

Review 7.  A review of soft-tissue sarcomas: translation of biological advances into treatment measures.

Authors:  Ngoc T Hoang; Luis A Acevedo; Michael J Mann; Bhairavi Tolani
Journal:  Cancer Manag Res       Date:  2018-05-10       Impact factor: 3.989

8.  The clinical use of biomarkers as prognostic factors in Ewing sarcoma.

Authors:  Annmeik M van Maldegem; Pancras Cw Hogendoorn; Andrew B Hassan
Journal:  Clin Sarcoma Res       Date:  2012-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.